Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin.

Antimicrobial Agents and Chemotherapy
H C NeuK P Fu

Abstract

The in vitro activity of ceftriaxone (Ro 13-9904), a parenteral cephalosporin, was compared with that of other beta-lactam antibiotics. the compound was less active against Staphylococcus aureus and Staphylococcus epidermidis than was cephalothin or cefamandole, but it was comparable to cefoxitin, cefotaxime, and moxalactam in inhibiting most isolates of S. aureus at 3.1 microgram/ml. Ro 13-9904 inhibited Streptococcus pyogenes and Streptococcus pneumoniae at concentrations below 0.25 microgram/ml, but Streptococcus faecalis required concentrations above 25 microgram/ml. Neisseria gonorrhoeae and Haemophilus influenzae were inhibited at concentrations similar to those of cefotaxime, less than 0.1 microgram/ml. Ro 13-9904 was as active as cefotaxime and moxalactam against most Enterobacteriaceae and was the most active agent tested against Proteus, inhibiting all strains tested at 0.006 microgram/ml. Ro 13-9904 was slightly less active than moxalactam or cefoxitin against Bacteroides fragilis, requiring more than 100 microgram/ml to inhibit 90% of isolates, and it was less active than cefoperazone against Pseudomonas aeruginosa. Presence of serum, alteration of pH, and use of various media did not change the inhibitory levels. B...Continue Reading

References

Aug 1, 1979·Antimicrobial Agents and Chemotherapy·H C NeuP Aswapokee
Aug 1, 1979·Antimicrobial Agents and Chemotherapy·H C NeuK Kung
Apr 1, 1972·Antimicrobial Agents and Chemotherapy·C H O'CallaghanA H Shingler
Apr 1, 1980·Antimicrobial Agents and Chemotherapy·K P Fu, H C Neu

❮ Previous
Next ❯

Citations

Jan 1, 1986·European Journal of Clinical Pharmacology·A A HolazoM Parsonnet
Jan 1, 1988·Infection·E P Espaze, A E Reynaud
Feb 1, 1986·European Journal of Clinical Microbiology·K MachkaI Braveny
Oct 1, 1983·European Journal of Clinical Microbiology·W M Scheld
Oct 1, 1983·European Journal of Clinical Microbiology·K Machka, R Dietz
Oct 1, 1983·European Journal of Clinical Microbiology·J D Baumgartner, M P Glauser
Mar 5, 2002·Journal of Veterinary Pharmacology and Therapeutics·M RebueltoR Hallu
Jun 1, 1982·Antimicrobial Agents and Chemotherapy·H L Muytjens, J van der Ros-van de Repe
Jul 1, 1982·Antimicrobial Agents and Chemotherapy·J W GnannC G Cobbs
Jul 1, 1982·Antimicrobial Agents and Chemotherapy·R W Bradsher
Aug 1, 1982·Antimicrobial Agents and Chemotherapy·R D Rolfe, S M Finegold
Jan 1, 1983·Antimicrobial Agents and Chemotherapy·R Latif, A S Dajani
Feb 1, 1983·Antimicrobial Agents and Chemotherapy·M J BittnerK B Crossley
Apr 1, 1983·Antimicrobial Agents and Chemotherapy·P SalvadorG P Bodey
May 1, 1983·Antimicrobial Agents and Chemotherapy·L J EronD M Poretz
Jan 1, 1984·Antimicrobial Agents and Chemotherapy·C S BryanJ D Gangemi
Apr 1, 1984·Antimicrobial Agents and Chemotherapy·I H PatelS J Berman
Feb 1, 1985·Antimicrobial Agents and Chemotherapy·B L CongeniQ T Box
Apr 1, 1985·Antimicrobial Agents and Chemotherapy·F M GordinJ Mills
Jul 1, 1985·Antimicrobial Agents and Chemotherapy·S LarssonT Moestrup
Jul 1, 1986·Antimicrobial Agents and Chemotherapy·A S BayerI K Blomquist
May 1, 1989·Antimicrobial Agents and Chemotherapy·R ShawarT G Cleary
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·M J EstebanF Rius
Oct 1, 1994·Antimicrobial Agents and Chemotherapy·G AcharyaC A Bradley
Jan 25, 2003·Antimicrobial Agents and Chemotherapy·M RebueltoM Rubio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.